Results 171 to 180 of about 246,302 (259)

Clinical Effects of Doxycycline on Skin Diseases with Bacterial Infection

The Nishinihon Journal of Dermatology, 1977
SHIMIZU, Yasuyuki, ASO, Miki, KANBE, Naoto, INOUE, Taeko, HASUO, Motoko, TAKEHARA, Naohide, MIHARA, Motoyuki, SHIMAO, Shuhei   +7 more
openaire   +1 more source

Impact of IL-4/IL-13 Blockade with Dupilumab on the Microbiome in Type 2 Inflammatory Diseases: A Systematic Review. [PDF]

Curr Allergy Asthma Rep
Mari PV, Carriera L, Saviano A, Ricci A, Coppola A, Ielo S, Lipsi R, Dodaj M, Gennari F, Gullà M, Stivalini D, Pellegrino MG, Migneco A, De Corso E, Ojetti V.   +14 more
europepmc   +1 more source

The sRNA vvrr1 Modulates the VarS/VarA‐Csr System via LeuO to Regulate Biofilm Formation and Virulence in Vibrio alginolyticus

Animal Research and One Health, EarlyView.
vvrr1, a small RNA, post‐transcriptionally represses the transcriptional regulator LeuO, which directly inhibits the VarS/VarA two‐component system. This triggers a Csr cascade that relieves LuxO repression, ultimately modulating exopolysaccharide production to control biofilm formation and virulence in Vibrio alginolyticus.
Theerakamol Pengsakul, Lei Wen, Lingmin Zhao, Bei Huang, Jiang Zheng, Binfu Xu, Lixing Huang   +6 more
wiley   +1 more source

T cells, the Next Big Target in Axial Spondyloarthritis?

Arthritis &Rheumatology, EarlyView.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

The Gut-Oral-Skin-Heart Microbiota Axis and Oxidative Stress: Where Have We Been and Where Are We Going. [PDF]

Dermatol Ther (Heidelb)
Girna I, Kuban-Jankowska A, Jakubczyk-Slabicka A, Kosiński A, Gruchała M, Górska-Ponikowska M.   +5 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Seasonal Dynamics of Skin Microbiota and Metabolites in Transhumant-Grazed Altay Sheep. [PDF]

Microorganisms
Li X, Qin Z, Wang H, Tao X, Xia J, Zhao Y, Yi P, Ma Y, Wang X, Ma X, Li N, Zhong Q, Yao G.   +12 more
europepmc   +1 more source

Increased Plasma Microbial tDR‐1 in At‐Risk Individuals Is Associated With Decreased Conversion to Clinical Rheumatoid Arthritis and Reduces an In Vitro Macrophage Type 1 Interferon Response

Arthritis &Rheumatology, EarlyView.
Objective Microbial small RNAs can regulate human genes. Higher plasma concentrations of microbial transfer RNA (tRNA)‐derived RNA‐1 (tDR‐1) were previously associated with lower rheumatoid arthritis (RA) disease activity. This study examined whether tDR‐1 concentrations differ in anticyclic citrullinated peptide‐3 positive (CCP3+) at‐risk individuals (
Anastasiia Phothisane, Tulsi K. Joishy, Carolina Ramirez‐Becerra, Qiong Wu, Jennifer Seifert, Marie L. Feser, Jill M. Norris, M. Kristen Demoruelle, LauraKay Moss, Kevin D. Deane, V. Michael Holers, Michelle J. Ormseth   +11 more
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Risk of skin and subcutaneous diseases in paediatric HIV-exposed uninfected individuals in the USA. [PDF]

Br J Dermatol
El Banna G, Wishner S, Baker N, Peacker BL, Braun N, Ma KS, Chen ST, Bebell LM.   +7 more
europepmc   +1 more source